Details for Patent: 11,311,498
✉ Email this page to a colleague
Which drugs does patent 11,311,498 protect, and when does it expire?
Patent 11,311,498 protects EPIDIOLEX and is included in one NDA.
This patent has forty-eight patent family members in eleven countries.
Summary for Patent: 11,311,498
Title: | Use of cannabinoids in the treatment of epilepsy |
Abstract: | The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). |
Inventor(s): | Guy; Geoffrey (Cambridge, GB), Wright; Stephen (Cambridge, GB), Devinsky; Orrin (New York, NY) |
Assignee: | GW Research Limited (Cambridge, GB) |
Application Number: | 14/741,829 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,311,498
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH DRAVET SYNDROME | ⤷ Try a Trial | ||||
Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,311,498
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
United Kingdom | 1410771 | Jun 17, 2014 |
International Family Members for US Patent 11,311,498
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2015275886 | ⤷ Try a Trial | |||
Australia | 2015275887 | ⤷ Try a Trial | |||
Australia | 2020217417 | ⤷ Try a Trial | |||
Australia | 2020220135 | ⤷ Try a Trial | |||
Australia | 2022202119 | ⤷ Try a Trial | |||
Australia | 2022209295 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |